Robert Mabry

Robert has contributed to the research and development of multiple biologic programs, including several currently under clinical evaluation and the approval of Sintilumab, a PD-1 mAb. He joins Orna from Takeda Pharmaceuticals, where he led the discovery and optimization of biological candidates and provided strategic support in overseeing their scientific operations. Prior to Takeda, Robert served as Vice President, Protein Sciences for Cogen Therapeutics, now Repertoire Immune Medicines. During his time as head of the department, he was responsible for protein engineering, antibody technology, protein production, and analytics. Robert has also held positions at Jounce Therapeutics, Adimab, ZymoGenetics, and ImClone Systems. He received his Ph.D. in Biochemistry from the University of Texas at Austin and a B.A. in Biology and Biochemistry from Baylor University.